Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Stefano Tarantolo (NPI 1205816667)

Field	Value
Entity Type	Individual
Organization	Stefano Tarantolo
Address	8303 Dodge St
City	Omaha
State	NE
ZIP	68114
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 20, 2006

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

This provider’s billings are effectively single‑payer: Total Medicare revenue is $3.2M while Total Medicaid revenue is none (no Medicaid billing on file), indicating the practice’s commercial/Medicaid exposure is minimal and Medicare dominates reported revenue. Analysts should treat Medicare utilization and reimbursement shifts as the primary determinants of near‑term revenue performance.

Revenue is highly concentrated in a small set of biologic and infusion codes: the precomputed top 3 Medicare codes account for 69.5% of this provider’s total Medicare revenue, with J9144 representing 38.6%, J1569 19.8%, and J9271 11.1%. That concentration implies most income flows from a handful of high‑cost drugs rather than broad procedural diversity.

The code mix indicates an infusion‑center‑style hematology/oncology practice: very large volumes of J9144 (daratumumab), significant J1569 (immune globulin), and reported J9271 (pembrolizumab) combined with chemotherapy administration codes (96413, 96401, 96417) and supportive agents (J0897 denosumab, J0881 darbepoetin) point to routine outpatient biologic and chemotherapy administration plus supportive care. This pattern is consistent with a practice that both administers specialty oncology biologics and manages follow‑up office visits.

STEFA NO TARANTOLO is a dominant national participant for at least one drug class: J9144 is reported as 31.5K claims, $38 avg paid/claim, $1.2M revenue and ranks #12 of 615 providers nationally (98th percentile; extreme outlier, far above typical national volume for this code). That extreme outlier status for daratumumab signals unusually large daratumumab throughput relative to peers.

For immune globulin and rituximab biosimilars the standing is mixed: J1569 shows 17.1K claims, $36 avg paid/claim, $616K revenue and ranks #12 of 542 providers nationally (98th percentile; typical, unremarkable volume for this code), while Q5119 and Q5123 (rituximab biosimilars) appear materially above typical national volumes (Q5119 rank #14 of 335, 96th percentile; Q5123 rank #8 of 40, 82th percentile). In short, the practice shows both extraordinarily high IVIG/daratumumab volume and above‑typical participation in biosimilar rituximab.

Not all top biologics are high relative to national peers: J9271 (pembrolizumab) accounts for $344.1K and 11.1% of Medicare revenue but ranks #1400 of 1841 providers nationally (24th percentile; typical, unremarkable volume). This suggests the provider’s biologic mix is skewed toward some agents (daratumumab, IVIG, rituximab biosimilars) while other high‑cost immunotherapies remain at modest or typical volumes.

High office visit throughput complements infusion activity: 99214 appears with 1.7K claims, $91 avg paid/claim, $157.4K revenue (5.1% of Medicare revenue) and ranks #2270 of 479517 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code). The coexistence of extreme outlier E/M volume and heavy infusion coding suggests sustained patient follow‑up and frequent in‑office management tied to infusion treatment schedules.

Operational and portfolio implications: with top‑three codes making up 69.5% of Medicare revenue and J9144 alone at 38.6%, the practice faces meaningful revenue sensitivity to utilization, pricing, or formulary shifts for a small set of biologics. Combined with no Medicaid billing on file and an NPI enumerated on 2006-01-20 (~20 years ago), this is an established, Medicare‑focused infusion practice where changes in Medicare policy or drug access could materially affect revenue.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

71 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	31,500	$40	$1.2M
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	17,110	$40	$616K
J9271	Injection, pembrolizumab, 1 mg	8,000	$40	$344.1K
J0897	Injection, denosumab, 1 mg	11,220	$20	$202K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,730	$90	$157.4K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	4,700	$20	$112.8K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	3,100	$30	$105.4K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,640	$30	$68.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	480	$100	$45.8K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	16,190	$1	$32.4K

Showing 1–10 of 71

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 71 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Stefano Tarantolo — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

71 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	23	30	14,400	$40	$671.6K
J9144	1	10	10,440	$40	$434.6K
J1569	1	10	5,980	$40	$224.3K
Q5119	1	10	4,700	$20	$114K
J1449	6	10	3,700	$30	$92.4K
Q5123	1	10	2,430	$30	$83.5K
J0897	9	200	2,040	$20	$62.7K
J0881	7	10	17,260	$1	$54.5K
J1439	12	30	25,880	$1	$26.4K
96413	10	80	60	$90	$18.2K

Showing 1–10 of 71

Related Providers

Other providers that share a Tax Identification Number (TIN) with Stefano Tarantolo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0
Yungpo Su	NE	Hematology & Oncology Physician	$1.9M	$0
Margaret Block	NE	Hematology & Oncology Physician	$1.7M	$0
Robert Langdon	NE	Hematology & Oncology Physician	$1.4M	$0
Muhammad Haroon	NE	Hematology & Oncology Physician	$1.4M	$0
Timothy Dorius	NE	Internal Medicine Physician	$1M	$0

Nearby Providers

Other providers in the same ZIP code as Stefano Tarantolo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Children's Hospital & Medical Center	NE	Children's Hospital	$0	$89.8M
Children's Physicians	NE	Pediatrics Physician	$0	$39.4M
Nebraska Pediatric Practice, Inc	NE	Pediatrics Physician	$0	$29M
Physicians Clinic Inc	NE	Family Medicine Physician	$0	$20.5M
Nebraska Methodist Hospital	NE	General Acute Care Hospital	$0	$14.5M
Smiles 4 Kids PC	NE	General Practice Dentistry	$0	$11.5M
Children's Hospital	NE	Pediatric Emergency Medicine (Pediatrics) Physician	$0	$8.4M
Nebraska Methodist Hospital	NE	Emergency Medicine Physician	$0	$5.3M
Unmc College Of Dentistry	NE	Dentist	$0	$4.8M
Stones Worth Stepping, P.C.	NE	Occupational Therapist	$0	$4.7M

Stefano Tarantolo — Billing Profile & Reimbursement Data

Sign up for Stefano Tarantolo — Billing Profile & Reimbursement Data policy alerts

Stefano Tarantolo — Billing Profile & Reimbursement Data

Sign up for Stefano Tarantolo — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References